Any current/future new fundraising through debt or equity?

The transcript on page 17 and surrounding pages does not mention any current or future plans for fundraising through debt or equity. The focus is primarily on capacity expansions and capital expenditure funded through internal accruals or operational cash flows. CapEx plans discussed include Rs. 70-80 Crores for acetonitrile plant in FY2023 and additional investments in methylamine and DMC plants. There is no explicit mention of raising funds via new debt or equity issuances in the discussed calls. The company appears focused on operational efficiency and phased expansions rather than fresh fu

Any current/future capex/capital investment/strategic investment?

Balaji Amines has planned multiple expansions including acetonitrile, dimethyl carbonate (DMC), methylamines, and DMF plants. CapEx of Rs. 70 to 80 Crores is planned for a new acetonitrile plant (50 TPD) expected to commence operations in FY2023. A new DMC plant is under construction aiming to start production by end of FY2022. Additional investments of Rs. 53 Crores are expected to complete the phase 1 Greenfield Project, with a total of Rs. 172 Crores already spent till June 30, 2021. CapEx for FY2022 is estimated around Rs. 50 to 60 Crores, including the final part of the ethylamine pla

Future growth expectations in sales/revenue/volumes?

After completion of all expansions (acetonitrile, DMC, ethylamine), Balaji Amines expects total volumes to be around 120,000 to 130,000 tonnes per annum, excluding the 50,000 tonnes greenfield methylamine capacity. Current specialty product volumes are approximately 20,000 to 25,000 tonnes annually; full expansion could increase this significantly. Revenue guidance for the company is around Rs. 1,800 to 2,000 Crores in two years, with potential to exceed Rs. 2,000 Crores if new DMF plant also materializes. The ethylamine plant, recently commissioned, has reached over 90% capacity utiliza

Future growth expectations in earnings/operating earnings/profits/EPS?

Capacity utilization is increasing from 20-30% earlier to 40% now, expected to reach 60-70%, leading to further profitability improvement. Sustainable EBITDA margin expected at 20-23% long-term; currently achieving 28-30% due to short supply and strong demand. Revenues projected to rise above Rs. 1,800 to Rs. 2,000 Crores in 2 years post expansions, potentially Rs. 2,000-2,500 Crores with new DMF plant. New ethylamine and DMC plants expected to generate Rs. 200-300 Crores and Rs. 150 Crores of revenue annually at full utilization. EPS grew significantly from Rs. 10.17 (Q1 FY2021) to Rs

Balaji AminesQ1 FY22Chemicals & Petrochemicals

Balaji Amines Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,848.8P/E: 29.3Market Cap: ₹6.0K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

After completion of all expansions (acetonitrile, DMC, ethylamine), Balaji Amines expects total volumes to be around 120,000 to 130,000 tonnes per annum, excluding the 50,000 tonnes greenfield methylamine capacity.
Current specialty product volumes are approximately 20,000 to 25,000 tonnes annually; full expansion could increase this significantly.
Revenue guidance for the company is around Rs. 1,800 to 2,000 Crores in two years, with potential to exceed Rs. 2,000 Crores if new DMF plant also materializes.
The ethylamine plant, recently commissioned, has reached over 90% capacity utilization and will continue to drive revenue growth (Rs. 200-300 Crores annually at full capacity).
The upcoming DMC plant is expected to start by the end of FY2022, targeting approx. Rs. 150 Crores in annual revenue.
Acetonitrile plant expansion (50 TPD) planned to commence operations in FY2023 with CapEx of Rs. 70-80 Crores.
Higher capacity utilization and improved price realizations are expected to enhance profitability alongside volume growth.

Margin guidance

Category 3

Capacity utilization is increasing from 20-30% earlier to 40% now, expected to reach 60-70%, leading to further profitability improvement.
Sustainable EBITDA margin expected at 20-23% long-term; currently achieving 28-30% due to short supply and strong demand.
Revenues projected to rise above Rs. 1,800 to Rs. 2,000 Crores in 2 years post expansions, potentially Rs. 2,000-2,500 Crores with new DMF plant.
New ethylamine and DMC plants expected to generate Rs. 200-300 Crores and Rs. 150 Crores of revenue annually at full utilization.
EPS grew significantly from Rs. 10.17 (Q1 FY2021) to Rs. 27.90 (Q1 FY2022), indicating growth momentum.
Expansion in product volumes targeting 120,000-130,000 tonnes combined (excluding methylamine greenfield capacity).
Increased capacity and new technology adoption expected to lower costs and improve margins further.

See what Balaji Amines management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript on page 17 and surrounding pages does not mention any current or future plans for fundraising through debt or equity.
The focus is primarily on capacity expansions and capital expenditure funded through internal accruals or operational cash flows.
CapEx plans discussed include Rs. 70-80 Crores for acetonitrile plant in FY2023 and additional investments in methylamine and DMC plants.
There is no explicit mention of raising funds via new debt or equity issuances in the discussed calls.
The company appears focused on operational efficiency and phased expansions rather than fresh fundraising drives.

Order book

The transcript provided on pages 1 to 19 of the Balaji Amines Limited Q1 FY2022 conference call does not contain any specific information or details about the company's current or expected order book or pending orders. The discussion predominantly focuses on capacity utilization, volume growth, product expansions, pricing, margins, and demand outlooks rather than specific order book data. - No explicit details on current order book or pending orders mentioned. - Focus is on capacity expansions (e.g. methylamine greenfield capacity, acetonitrile plant). - Discussion centers on utilization rates, volumes, and revenue guidance. - Expectation of improved utilization and profitability as new plants ramp up. - Demand for certain products remains strong, but no quantitative order book figures provided. Therefore, no specific data on order book or pending orders can be extracted from the available text.

See what Balaji Amines management said on order book — free account, 30 seconds.

Capex plans

Yes

Balaji Amines has planned multiple expansions including acetonitrile, dimethyl carbonate (DMC), methylamines, and DMF plants.
CapEx of Rs. 70 to 80 Crores is planned for a new acetonitrile plant (50 TPD) expected to commence operations in FY2023.
A new DMC plant is under construction aiming to start production by end of FY2022.
Additional investments of Rs. 53 Crores are expected to complete the phase 1 Greenfield Project, with a total of Rs. 172 Crores already spent till June 30, 2021.
CapEx for FY2022 is estimated around Rs. 50 to 60 Crores, including the final part of the ethylamine plant and DMC plant.
New methylamine plant capex is expected to begin in FY2023, with exact costs to be clarified later.
A new co-generation power plant (4.9 MW) is planned to be operational within a few months to reduce costs.
No major backward integration beyond oxygen and power plants is planned due to scale and complexity.

Track Balaji Amines — get its next earnings analysis in your feed

How does Balaji Amines rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisBalaji Amines

Rev 2Mar 3

See where Balaji Amines sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Balaji Amines rank in Chemicals & Petrochemicals?

Compare Balaji Amines against every Chemicals & Petrochemicals company (Q1 FY22) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Balaji Amines's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Alufluoride Ltd (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →